fbpx
L. Maximilian Buja, MD

Dr. Buja is engaged in scholarly investigation, educational activities and clinical service while also serving in leadership roles. His subspecialty interest is cardiovascular pathology with research interests in myocardial cell injury, myocardial ischemia, atherosclerosis and cardiomyopathies. Dr. Buja teaches medical students, medical residents, clinical fellows, graduate students and research post-doctoral fellows. Show full bio

He also conducts a clinical practice in cardiovascular pathology providing staffing of autopsy cases and surgical pathology consultation of cardiac and vascular cases and interpretation of myocardial biopsies from referrals. He directs a cardiovascular pathology fellowship approved by the Texas Medical Board. Since the establishment of an Advanced Heart Failure Center on campus, he has served as the cardiovascular pathologist for the Center and has provided staffing for over 100 heart transplants, numerous LVADs, and post-transplant myocardial biopsies for evaluation and grading of antibody-mediated and acute cellular rejection. Dr. Buja serves as a consultant in cardiovascular pathology for the Harris County Institute of Forensic Sciences. He serves as the Director of the DPALM Autopsy Service at the affiliated teaching hospitals and has been an advocate of the importance of the autopsy as a tool in medical research and quality control in healthcare. He is the editor-in-chief of Cardiovascular Pathology, the official journal of the Society for Cardiovascular Pathology. He also serves as the Executive Director of The Texas Medical Center Library located adjacent to the medical school.

See Publications

Texas Heart Institute Positions

  • Chief, Cardiovascular Pathology Research
  • Editorial Board, Texas Heart Institute Journal

Interests

  • Cardiovascular pathology
  • Atherosclerosis
  • Ischemic heart disease
  • Cardiomyopathies

Education

  • Undergraduate:

    Loyola University

  • Medical School:

    Tulane University School of Medicine

  • Internship:

    Charity Hospital in New Orleans

  • Residency:

    National Cancer Institute

  • Fellowships:

    National Cancer Institute

Academic & Clinical Affiliations

  • McGovern Medical School, University of Texas Health Science Center at Houston

Honors, Awards and Memberships

Publications

Akkanti, B. H., Hussain, R., Patel, M. K. et al. (2023). Correction: Deadly combination of Vaping-lnduced lung injury and influenza: case report. Diagn Pathol 18, 58. https://doi.org/10.1186/s13000-023-01345-5.
Maximilian Buja, L. (2023). In Memoriam: Tomas Klima, MD (1931-2022). Tex Heart Inst J 50, e228027. https://doi.org/10.14503/THIJ-22-8027.
Kelly, K. L., Lin, P. T., Basso, C. et al. (2023). Sudden cardiac death in the young: A consensus statement on recommended practices for cardiac examination by pathologists from the Society for Cardiovascular Pathology. Cardiovasc Pathol 63, 107497. https://doi.org/10.1016/j.carpath.2022.107497.
Jyothula, S. S. K., Peters, A., Liang, Y. et al. (2022). Fulminant lung fibrosis in non-resolvable COVID-19 requiring transplantation. EBioMedicine 86, 104351. https://doi.org/10.1016/j.ebiom.2022.104351.
Salas De Armas, I. A., Buja, L. M., Patel, M. K. et al. (2022). Aortic root dissection due to an automated fastener device. Tex Heart Inst J 49, e207531. https://doi.org/10.14503/THIJ-20-7531.
Lu, G., Zhu, P., Rao, M. et al. (2022). Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. J Neurooncol. https://doi.org/10.1007/s11060-022-04144-y.
da Graça Cabreira, M., Wang, X., Critsinelis, A. et al. (2022). Environmental oxygen affects ex vivo growth and proliferation of mesenchymal progenitors by modulating mitogen-activated protein kinase and mammalian target of rapamycin signaling. Cytotherapy, S1465-3249(22)00707–1. https://doi.org/10.1016/j.jcyt.2022.06.005.
Yohannan, B., Rios, A. and Buja, M. (2022). Durable remission in hodgkin lymphoma treated with one cycle of bleomycin, vinblastine, dacarbazine and two doses of nivolumab and brentuximab vedotin. J Hematol 11, 154–158. https://doi.org/10.14740/jh1035.
Achim, A., Savaria, B. U. and Buja, L. M. (2022). Commentary on the enigma of small vessel disease in hypertrophic cardiomyopathy: is invasive assessment of microvascular resistance a novel independent predictor of prognosis? Cardiovasc Pathol 60, 107448. https://doi.org/10.1016/j.carpath.2022.107448.
Chattopadhyay, A., Guan, P., Majumder, S. et al. (2022). Preventing cholesterol-induced perk (protein kinase rna-like endoplasmic reticulum kinase) signaling in smooth muscle cells blocks atherosclerotic plaque formation. Arterioscler Thromb Vasc Biol, 101161ATVBAHA121317451. https://doi.org/10.1161/ATVBAHA.121.317451.